These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 20716053

  • 21. A multidisciplinary study of 3-(β-d-glucopyranosyl)-5-substituted-1,2,4-triazole derivatives as glycogen phosphorylase inhibitors: Computation, synthesis, crystallography and kinetics reveal new potent inhibitors.
    Kun S, Begum J, Kyriakis E, Stamati ECV, Barkas TA, Szennyes E, Bokor É, Szabó KE, Stravodimos GA, Sipos Á, Docsa T, Gergely P, Moffatt C, Patraskaki MS, Kokolaki MC, Gkerdi A, Skamnaki VT, Leonidas DD, Somsák L, Hayes JM.
    Eur J Med Chem; 2018 Mar 10; 147():266-278. PubMed ID: 29453094
    [Abstract] [Full Text] [Related]

  • 22. Glycogen phosphorylase inhibitors.
    Henke BR, Sparks SM.
    Mini Rev Med Chem; 2006 Aug 10; 6(8):845-57. PubMed ID: 16918491
    [Abstract] [Full Text] [Related]

  • 23. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of designed ligands by a multiple screening method: application to glycogen phosphorylase inhibitors constructed with a variety of approaches.
    So SS, Karplus M.
    J Comput Aided Mol Des; 2001 Jul 27; 15(7):613-47. PubMed ID: 11688944
    [Abstract] [Full Text] [Related]

  • 25. Glucose-lowering in a db/db mouse model by dihydropyridine diacid glycogen phosphorylase inhibitors.
    Ogawa AK, Willoughby CA, Bergeron R, Ellsworth KP, Geissler WM, Myers RW, Yao J, Harris G, Chapman KT.
    Bioorg Med Chem Lett; 2003 Oct 20; 13(20):3405-8. PubMed ID: 14505637
    [Abstract] [Full Text] [Related]

  • 26. From structure--based to knowledge--based drug design through x-ray protein crystallography: sketching glycogen phosphorylase binding sites.
    Chrysina ED, Chajistamatiou A, Chegkazi M.
    Curr Med Chem; 2011 Oct 20; 18(17):2620-9. PubMed ID: 21568887
    [Abstract] [Full Text] [Related]

  • 27. Modeling and informatics in designing anti-diabetic agents.
    Bharatam PV, Patel DS, Adane L, Mittal A, Sundriyal S.
    Curr Pharm Des; 2007 Oct 20; 13(34):3518-30. PubMed ID: 18220788
    [Abstract] [Full Text] [Related]

  • 28. Structure-activity analysis of the purine binding site of human liver glycogen phosphorylase.
    Ekstrom JL, Pauly TA, Carty MD, Soeller WC, Culp J, Danley DE, Hoover DJ, Treadway JL, Gibbs EM, Fletterick RJ, Day YS, Myszka DG, Rath VL.
    Chem Biol; 2002 Aug 20; 9(8):915-24. PubMed ID: 12204691
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Synthesis, in vitro ADME profiling and in vivo pharmacological evaluation of novel glycogen phosphorylase inhibitors.
    Miao GX, Wang YD, Yan ZW, Zhang LY.
    Bioorg Med Chem Lett; 2020 Jul 15; 30(14):127117. PubMed ID: 32527535
    [Abstract] [Full Text] [Related]

  • 33. Glycogen phosphorylase inhibitors: a patent review (2008 - 2012).
    Gaboriaud-Kolar N, Skaltsounis AL.
    Expert Opin Ther Pat; 2013 Aug 15; 23(8):1017-32. PubMed ID: 23627914
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Glucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Czifrák K, Larini P, Demontrond F, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Docsa T, Gergely P, Somsák L, Praly JP, Azay-Milhau J, Vidal S.
    Org Biomol Chem; 2020 Feb 07; 18(5):931-940. PubMed ID: 31922157
    [Abstract] [Full Text] [Related]

  • 36. 2-Oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors: Design, synthesis and structure-activity relationship study.
    Loughlin WA, Jenkins ID, Karis ND, Schweiker SS, Healy PC.
    Eur J Med Chem; 2016 Mar 23; 111():1-14. PubMed ID: 26851835
    [Abstract] [Full Text] [Related]

  • 37. An Improved Comparative Docking Approach for Developing Specific Glycogen Phosphorylase Inhibitors Using Pentacyclic Triterpenes.
    Konkimalla VB.
    Curr Top Med Chem; 2017 Mar 23; 17(14):1640-1645. PubMed ID: 27823565
    [Abstract] [Full Text] [Related]

  • 38. Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors.
    Birch AM, Kenny PW, Simpson I, Whittamore PR.
    Bioorg Med Chem Lett; 2009 Feb 01; 19(3):850-3. PubMed ID: 19103484
    [Abstract] [Full Text] [Related]

  • 39. Discovering benzamide derivatives as glycogen phosphorylase inhibitors and their binding site at the enzyme.
    Chen L, Li H, Liu J, Zhang L, Liu H, Jiang H.
    Bioorg Med Chem; 2007 Nov 01; 15(21):6763-74. PubMed ID: 17719791
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of glycogenolysis towards antidiabetic and other therapies.
    Somsák L.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1091-2. PubMed ID: 20716057
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.